Please wait

Exhibit 107

Calculation of Filing Fee Table

Form S-3

(Form Type)

ARS Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered Securities

 

                 
     Security 
Type
 

Security

Class

Title

 

Fee

Calculation 

Rule 

  Amount
 Registered 
 

Proposed
Maximum
 Offering

Price Per 

Unit

  Maximum
 Aggregate 
Offering
Price
  Fee
 Rate 
 

Amount of
 Registration 

Fee

                 
 Fees to Be Paid    Equity  

Common Stock,

par value

$0.0001 per

share

 

 Rule 456(b)  and

Rule 457(r)

  (1)   (2)   (2)   (3)   (3)
                 
    Equity  

Preferred Stock,

par value

$0.0001 per

share

 

Rule 456(b) and

Rule 457(r)

  (1)   (2)   (2)   (3)   (3)
                 
    Debt   Debt Securities  

Rule 456(b) and

Rule 457(r)

  (1)   (2)   (2)   (3)   (3)
                 
    Other   Warrants  

Rule 456(b) and

Rule 457(r)

  (1)   (2)   (2)   (3)   (3)
                 
    Equity  

Common Stock,

par value

$0.0001 per

share

  Rule 457(o)   $200,000,000   (2)   $200,000,000   $0.00015310   $30,620
                 

 Fees Previously 

Paid 

               
           
    Total Offering Amounts   (2)   $200,000,000     $30,620
           
    Total Fees Previously Paid        
           
    Total Fee Offsets         $23,175 (4)
           
    Net Fee Due               $7,445


Table 2: Fee Offset Claims and Sources

 

                       
     Registrant
or Filer
Name
  Form
or
Filing
Type
  File
Number
  Initial
Filing
Date
  Filing
Date
  Fee Offset
Claimed
  Security
Type
Associated
with Fee
Offset
Claimed
  Security
Title
Associated
with Fee
Offset
Claimed
  Unsold
Securities
Associated
with Fee
Offset
Claimed
  Unsold
Aggregate
Offering
Amount
Associated
with Fee
Offset
Claimed
  Fee Paid
with Fee
Offset
Source
 
Rule 457(p)
                       
 Fee Offset  Claims  

ARS Pharmaceuticals, Inc.

(formerly Silverback

Therapeutics, Inc.)

  S-3   333-261979   January 3, 2022     $23,175   Unallocated (Universal) Shelf   Unallocated (Universal) Shelf   Unallocated (Universal) Shelf   $250,000,000 (4)   — 
                       
Fee Offset Sources   ARS Pharmaceuticals, Inc. (formerly Silverback Therapeutics, Inc.)   S-3   333-261979 (4)   N/A   January 3, 2022   —    —    —    —    —    $23,175 (4)

 

(1)

There are being registered hereunder such indeterminate number of shares of common stock, such indeterminate number of shares of preferred stock, such indeterminate principal amount of debt securities and such indeterminate number of warrants to purchase common stock, preferred stock or debt securities. The securities registered also include such indeterminate amount of all securities previously issued hereunder. The securities registered also include such indeterminate number of shares of common stock, preferred stock and amount of debt securities as may be issued upon conversion of or exchange for debt securities that provide for conversion or exchange, upon exercise of warrants or pursuant to the antidilution provisions of any such securities. In addition, pursuant to Rule 416 under the Securities Act of 1933, as amended (“Securities Act”), the shares being registered hereunder include such indeterminate number of shares of common stock and preferred stock as may be issuable with respect to the shares being registered hereunder as a result of stock splits, stock dividends or similar transactions.

(2)

The proposed maximum per security and aggregate offering prices per class of securities will be determined from time to time by the registrant in connection with the issuance by the registrant of the securities registered hereunder and is not specified as to each class of security. Separate consideration may or may not be received for securities that are issuable on exercise, conversion or exchange of other securities.

(3)

The registrant is relying on Rules 456(b) and 457(r) under the Securities Act to defer payment of the entire registration fee. In connection with the securities offered hereby, the registrant will pay “pay-as-you-go registration fees” in accordance with Rule 456(b) under the Securities Act. The registrant will calculate the registration fee applicable to an offer of securities pursuant to this registration statement based on the fee rate in effect on the date of such fee payment.

(4)

Pursuant to Rule 457(p) under the Securities Act, the registrant hereby offsets a portion of the registration fee due hereunder by $23,175.00, which represents the portion of the registration fee previously paid with respect to unsold securities registered on the registrant’s Registration Statement on Form S-3 (File No. 333-261979) filed with the Securities and Exchange Commission on January 3, 2022 and declared effective on January 13, 2022 (the “Prior Registration Statement”), that was paid on January 3, 2022, in connection with the filing of the Prior Registration Statement. Of the $250,000,000 of securities registered on the Prior Registration Statement, for which a contemporaneous fee payment of $23,175 was paid, all of the securities remain unsold, leaving the full $23,175.00 previously paid fees available for future offset (calculated at the fee rate in effect on the filing date of the Prior Registration Statement). All offerings under the Prior Registration Statement have terminated.